S&P 500   3,378.15 (+0.53%)
DOW   28,109.53 (+1.14%)
QQQ   269.41 (-0.33%)
AAPL   446.00 (-1.09%)
MSFT   206.78 (-0.71%)
FB   264.01 (+0.38%)
GOOGL   1,501.35 (+0.30%)
AMZN   3,135.50 (-0.40%)
NVDA   440.29 (-1.41%)
CGC   17.55 (-2.12%)
BABA   250.51 (+0.96%)
TSLA   1,402.42 (-1.14%)
GE   6.82 (+2.25%)
MU   48.76 (-0.79%)
AMD   79.18 (-3.72%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.08 (-1.37%)
GILD   68.26 (-0.36%)
NFLX   472.76 (-2.20%)
DIS   131.47 (+2.08%)
BAC   27.44 (+3.31%)
BA   186.33 (+3.86%)
S&P 500   3,378.15 (+0.53%)
DOW   28,109.53 (+1.14%)
QQQ   269.41 (-0.33%)
AAPL   446.00 (-1.09%)
MSFT   206.78 (-0.71%)
FB   264.01 (+0.38%)
GOOGL   1,501.35 (+0.30%)
AMZN   3,135.50 (-0.40%)
NVDA   440.29 (-1.41%)
CGC   17.55 (-2.12%)
BABA   250.51 (+0.96%)
TSLA   1,402.42 (-1.14%)
GE   6.82 (+2.25%)
MU   48.76 (-0.79%)
AMD   79.18 (-3.72%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.08 (-1.37%)
GILD   68.26 (-0.36%)
NFLX   472.76 (-2.20%)
DIS   131.47 (+2.08%)
BAC   27.44 (+3.31%)
BA   186.33 (+3.86%)
S&P 500   3,378.15 (+0.53%)
DOW   28,109.53 (+1.14%)
QQQ   269.41 (-0.33%)
AAPL   446.00 (-1.09%)
MSFT   206.78 (-0.71%)
FB   264.01 (+0.38%)
GOOGL   1,501.35 (+0.30%)
AMZN   3,135.50 (-0.40%)
NVDA   440.29 (-1.41%)
CGC   17.55 (-2.12%)
BABA   250.51 (+0.96%)
TSLA   1,402.42 (-1.14%)
GE   6.82 (+2.25%)
MU   48.76 (-0.79%)
AMD   79.18 (-3.72%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.08 (-1.37%)
GILD   68.26 (-0.36%)
NFLX   472.76 (-2.20%)
DIS   131.47 (+2.08%)
BAC   27.44 (+3.31%)
BA   186.33 (+3.86%)
S&P 500   3,378.15 (+0.53%)
DOW   28,109.53 (+1.14%)
QQQ   269.41 (-0.33%)
AAPL   446.00 (-1.09%)
MSFT   206.78 (-0.71%)
FB   264.01 (+0.38%)
GOOGL   1,501.35 (+0.30%)
AMZN   3,135.50 (-0.40%)
NVDA   440.29 (-1.41%)
CGC   17.55 (-2.12%)
BABA   250.51 (+0.96%)
TSLA   1,402.42 (-1.14%)
GE   6.82 (+2.25%)
MU   48.76 (-0.79%)
AMD   79.18 (-3.72%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.08 (-1.37%)
GILD   68.26 (-0.36%)
NFLX   472.76 (-2.20%)
DIS   131.47 (+2.08%)
BAC   27.44 (+3.31%)
BA   186.33 (+3.86%)
Log in

NASDAQ:CTICCTI BioPharma Stock Price, Forecast & News

$1.27
-0.03 (-2.31 %)
(As of 08/11/2020 02:02 PM ET)
Add
Compare
Today's Range
$1.27
Now: $1.27
$1.29
50-Day Range
$1.15
MA: $1.38
$1.78
52-Week Range
$0.62
Now: $1.27
$1.95
Volume2,705 shs
Average Volume1.17 million shs
Market Capitalization$93.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Read More
CTI BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
Phone206-282-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.35 million
Book Value$0.31 per share

Profitability

Net Income$-40,020,000.00

Miscellaneous

Employees46
Market Cap$93.57 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$1.27
-0.03 (-2.31 %)
(As of 08/11/2020 02:02 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

How has CTI BioPharma's stock been impacted by Coronavirus?

CTI BioPharma's stock was trading at $0.8901 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTIC shares have increased by 42.7% and is now trading at $1.27.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CTI BioPharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CTI BioPharma
.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for CTI BioPharma
.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) issued its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.07.
View CTI BioPharma's earnings history
.

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma shares reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CTIC?

3 equities research analysts have issued 1 year price objectives for CTI BioPharma's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate CTI BioPharma's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 175.6% from the stock's current price.
View analysts' price targets for CTI BioPharma
.

Has CTI BioPharma been receiving favorable news coverage?

Headlines about CTIC stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CTI BioPharma earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about CTI BioPharma
.

Are investors shorting CTI BioPharma?

CTI BioPharma saw a drop in short interest in January. As of January 15th, there was short interest totaling 194,800 shares, a drop of 32.9% from the December 31st total of 290,500 shares. Based on an average daily volume of 432,100 shares, the short-interest ratio is presently 0.5 days. Currently, 0.4% of the company's shares are short sold.
View CTI BioPharma's Short Interest
.

Who are some of CTI BioPharma's key competitors?

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and AEterna Zentaris (AEZS).

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the following people:
  • Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 53)
  • Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)
  • Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 65)
  • Mr. Bruce J. Seeley, Exec. VP & COO (Age 55)
  • Mr. Ed Bell, Sr. Director of Investor Relations

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

Who are CTI BioPharma's major shareholders?

CTI BioPharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.04%).
View institutional ownership trends for CTI BioPharma
.

Which major investors are buying CTI BioPharma stock?

CTIC stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for CTI BioPharma
.

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $1.27.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $93.57 million and generates $3.35 million in revenue each year. CTI BioPharma employs 46 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is www.ctibiopharma.com.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.